Kanya Rajangam
President, Chief Medical Officer & Head of Research & Development Senti Biosciences Inc.
Seminars
Thursday 17th September 2026
Roundtable Discussion: Utilizing Biomarkers to Guide Patient Selection, Predict Responses & Improve Safety
2:35 pm
- Exploring predictive patient and donor biomarkers to determine the cell therapy modalities best suited for individual patients and disease contexts
- Identifying pre-infusion and on-treatment biomarker signals to understand response dynamics and guide clinical decision making
- Evaluating immune fitness and safety related biomarkers to identify patients at risk, anticipate challenges, and enhance therapeutic outcomes
Thursday 17th September 2026
First In Class Logic Gated Allogeneic CAR Cell Therapy with RMAT Designation Phase 1 Data
3:20 pm
- Demonstrating clinical outcomes from phase 1 trials
- Exploring predictive biomarkers to optimize response, safety and trial design in allogeneic therapies
- Showcasing how clinical data enabled regulatory progress and informed pivotal study strategies
